- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S7530
| Related Targets | PKC ROCK Bcr-Abl |
|---|---|
| Other TGF-beta/Smad Products | SB431542 LDN-193189 Galunisertib (LY2157299) LY2109761 LDN-193189 Dihydrochloride SIS3 Hydrochloride RepSox (E-616452) DMH1 A-83-01 SRI-011381 (C381) |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| Sf9 | Function assay | Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay, IC50 = 0.007 μM. | 24786585 | |||
| Sf9 | Function assay | Inhibition of human recombinant GST-fused ALK5 expressed in Sf9 insect cells using casein as substrate by proprietary radioisotopic protein kinase assay, IC50 = 0.00967 μM. | 26483198 | |||
| 4T1 | Function assay | 24 hrs | Inhibition of ALK5 in mouse 4T1 cells assessed as inhibition of TGFbeta1-induced luciferase activity after 24 hrs by luciferase reporter gene assay, IC50 = 0.0121 μM. | 24786585 | ||
| HaCaT | Function assay | 24 hrs | Inhibition of ALK5 in human HaCaT cells assessed as inhibition of TGFbeta1-induced luciferase activity after 24 hrs by luciferase reporter gene assay, IC50 = 0.0165 μM. | 24786585 | ||
| HEK293 | Function assay | 3 to 5.7 mins | Inhibition of human ERG channel expressed in HEK293 cells after 3 to 5.7 mins by whole-cell patch clamp technique, IC50 = 31.04 μM. | 24786585 | ||
| B16 | Antitumor assay | 2.5 mg/kg | Antitumor activity against mouse B16 cells in mouse assessed as suppression of tumor volume at 2.5 mg/kg, po qd relative to vehicle-treated control | 24786585 | ||
| B16 | Antitumor assay | 2.5 mg/kg | Antitumor activity against mouse B16 cells in mouse assessed as inhibition of tumor growth at 2.5 mg/kg, po qd relative to vehicle-treated control | 24786585 | ||
| B16 | Antitumor assay | 2.5 mg/kg | Antitumor activity against mouse B16 cells in mouse assessed as inhibition of lymph node metastasis at 2.5 mg/kg, po qd relative to vehicle-treated control | 24786585 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 79 mg/mL
(197.78 mM)
Ethanol : 79 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 399.42 | Formula | C22H18FN7 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1352608-82-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | EW-7197 | Smiles | CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4 | ||
| Targets/IC50/Ki |
ALK5
(Cell-free assay) 11 nM
ALK4
(Cell-free assay) 13 nM
|
|---|---|
| In vitro |
In HaCaT (3TP-luc) and 4T1 (3TP-luc) stable cells, 12b potently inhibits the TGF-β1-induced luciferase reporter activity with IC50 of 16.5 and 12.1 nM, respectively. EW-7197 inhibits TGFβ-induced Smad2 or Smad3 phosphorylation and the epithelial-to-mesenchymal transition (EMT) in TGFβ-treated breast cancer cells. In addition, EW-7197 also abrogates TGFβ1-induced tumor cell migration and invasion in breast cells.
|
| Kinase Assay |
Protein Kinase Assay
|
|
A radioisotopic protein kinase assay (HotSpot assay) is performed at Reaction Biology Corporation.
|
|
| In vivo |
In rats, EW-7197 shows an oral bioavailability of 51% with high systemic exposure (AUC) of 1426 ng×h/mL and maximum plasma concentration (Cmax) of 1620 ng/mL. EW-7197 also shows low toxicity on the cardiovascular system, central nervous system, and respiratory system. [1] In a mouse B16 melanoma model, EW-7197 (2.5 mg/kg daily p.o.) suppresses the progression of melanoma with enhanced cytotoxic T-lymphocyte (CTL) responses. EW-7197 enhances cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | α-CUG2 / α-E-cadherin / α-N-cadherin / α-vimentin α-p-Smad2 / α-Smad2/3 / α-Twist / α-Snail α-p-AKT / α-AKT / α-p-ERK / α-ERK / α-p-JNK / α-JNK / α-p-p38 / α-p38 |
|
27974707 |
| Immunofluorescence | Smad2 / Smad3 |
|
31496148 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.